Considering the clinical trials, which are currently exploring anti-CD47 antibodies against ovarian cancer, they aim to block this signal and enhance the immune system’s ability to eliminate cancer cells, offering a promising therapeutic strategy [123,146]. This evidence concerns the gene CD47 and cancer.